Abstracts Archive - Page 641 of 2607 - ACR Meeting Abstracts

Abstract Number: 0989 • ACR Convergence 2022
Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
Nandita Sarkar¹, Xuguang Hu¹, Nadia Tchao¹, Richard Furie², Alan Kivitz³, Stanley B Cohen⁴ and Kevin Gorski⁵, ¹Amgen Inc., South San Francisco, CA, ²Northwell Health, Great Neck, NY, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁵Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Regulatory T cells (Treg) are critical for maintaining self-tolerance and preventing autoimmunity, and IL-2 is essential for their development, survival and suppressive function. Defects…
Abstract Number: 1004 • ACR Convergence 2022
SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis
Raquel Granados¹, lourdes Ladehesa-Pineda², Maria Angeles Puche Larrubia³, Maxime Dougados⁴, Eduardo Collantes⁵ and Clementina Lopez-Medina⁶, ¹Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, ⁴Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ⁶Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain
Background/Purpose: Spondyloarthritis, (axial (axSpA), peripheral (pSpA)) and psoriatic arthritis (PsA)) share enthesitis as a hallmark clinical feature. Reliable clinical instruments have been developed to assess…
Abstract Number: 1005 • ACR Convergence 2022
Increasing the Proficiency for Scoring Sacroiliac Joint Radiographs According to the Modified New York Criteria for Ankylosing Spondylitis by Using an Online Real-time Iterative Calibration (RETIC) Module
Anna Hadsbjerg¹, Mikkel Østergaard², Joel Paschke³, Adrian Ciurea⁴, Michael Nissen⁵, Stephanie Wichuk⁶, Ashish J Mathew⁷, Marie Wetterslev⁸, Raphael Micheroli⁹, Susanne Pedersen¹⁰, Simon Krabbe¹⁰, Kristyna Bubova¹¹, Monika gregova¹², Alexander Bernatschek⁴, Maurice Donzallaz⁴, Burkhard Moeller¹³, Ziga Snoj¹⁴, Karlo Pintaric¹⁴, Manouk de Hooge¹⁵, Karel Gorican¹⁶, Robert G Lambert⁶ and Walter P Maksymowych¹⁷, ¹Copenhagen Center for Arthritis Research, COPECARE, Rigshospitalet, Glostrup, Denmark, ²Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ³CARE Arthritis LTD, Edmonton, AB, Canada, ⁴University Hospital Zurich, Zürich, Switzerland, ⁵Hopitaux Universitaires de Genève, Geneva, Switzerland, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Rigshospitalet, Copenhagen, Denmark, ⁸Rigshospitalet, Copenhagen, Glostrup, Denmark, ⁹University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, ¹⁰Rigshospitalet, København, Denmark, ¹¹First Faculty of Medicine, Charles University,, Prague, Czech Republic, ¹²Institue of Rheumatology, Prague, ¹³Inselspital - University Hospital Bern, Bern, Switzerland, ¹⁴Radiology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁵Ghent University Hospital, Luxembourg, Luxembourg, ¹⁶MSK radiology unit, Radiology section – Diagnostic department, Geneva University Hospitals, Geneva, Switzerland, ¹⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Radiographic assessment of the sacroiliac joints (SIJ) according to the modified New York (mNY) criteria is essential in the classification of ankylosing spondylitis, but…
Abstract Number: 1008 • ACR Convergence 2022
Endothelial Dysfunction in Axial Spondyloarthritis and Its Association with Clinical Disease Characteristics
lourdes Ladehesa-Pineda¹, Clementina Lopez-Medina², Maria Angeles Puche Larrubia³, Raquel Granados⁴ and Eduardo Collantes⁵, ¹Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ²Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, ⁴Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain
Background/Purpose: It has been described an increased presence of cardiovascular risk factors and subclinical atherosclerosis in patients with axial spondyloarthritis (axSpA). Several studies have shown…
Abstract Number: 1007 • ACR Convergence 2022
Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study
Lihi Eder¹, Charlene Compher², Helen Emanoilidis³, Ryan F. Quinn², Dafna Gladman⁴, Vinod Chandran⁵, Jose Scher⁶ and Alexis Ogdie⁷, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Pennsylvania, Philadelphia, PA, ³Women's College Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁵Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁶New York University School of Medicine, New York, NY, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic Arthritis (PsA) is associated with obesity and its related metabolic abnormalities. The role of diet as an adjunct therapy in PsA remains unclear.…
Abstract Number: 1009 • ACR Convergence 2022
Efficacy and Improvement in Patient-Reported Outcomes at Weeks 16 and 52 in Ixekizumab Treated Biological Naïve Patients with Radiographic Axial Spondyloarthritis Achieving Clinically Important Pain at Night Reduction at Week 16: Results from COAST-V Trial
Sofia Ramiro¹, Cédric Lukas², Michael Nissen³, Yves Schymura⁴, Khai Jing Ng⁴, Andrew Bradley⁴, Gabriel Doridot⁴, Soyi Liu-Leage⁵, Antoni Chan⁶ and James Cheng-Chung WEI⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ³Hopitaux Universitaires de Genève, Geneva, Switzerland, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Neuilly sur Seine, France, ⁶Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ⁷Chung Shan Medical University Hospital, Taichung, Taiwan
Background/Purpose: Ixekizumab (IXE), a monoclonal antibody that selectively targets interleukin IL-17A, has shown efficacy in patients with radiographic axial spondyloarthritis (r-axSpA). Spinal pain, in particular…
Abstract Number: 1006 • ACR Convergence 2022
Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled “Post Hoc” Analysis from Five Phase 3 Studies
Renaud FELTEN¹, Laura Widawski², Lionel Spielmann², Corine Gaillez³, Weibin Bao⁴, Hugh O’Neill⁵, jacques-eric gottenberg⁶, Pierre-Marie Duret² and Laurent Messer⁷, ¹Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Colmar Civilian Hospitals, Colmar, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Ireland Limited, Dublin, Ireland, ⁶Strasbourg University Hospital, Strasbourg, France, ⁷Colmar Civil Hospitals, Colmar, France
Background/Purpose: Hyperuricemia (HU), a common metabolic abnormality, may result in development of gout, which is an inflammatory arthritic condition1,2. Patients (pts) with psoriasis (PsO)/psoriatic arthritis…
Abstract Number: 0987 • ACR Convergence 2022
A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases
Stacey Dillon¹, Pille Harrison², Jason Lickliter³, Kristi Manjarrez¹, Alina Smith¹, Mary Lessig¹, Lori Blanchfield¹, Russell Sanderson¹, Allison Chunyk¹, Tiffany Blair¹, Amanda Enstrom¹, Martin Wolfson¹, Mark Rixon¹, Hany Zayed⁴, Rupert Davies¹ and Stanford Peng¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Taunton, United Kingdom, ³Nucleus Network, Melbourne, Australia, ⁴Alpine Immune Sciences, San Francisco, CA
Background/Purpose: B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are tumor necrosis factor (TNF) superfamily members that bind TACI (transmembrane activator and CAML…
Abstract Number: 1014 • ACR Convergence 2022
Is Radiographic Axial Involvement Associated with Syndesmophyte Development After 2 Years in PsA Patients?
Manouk de Hooge¹, Alla Alexeevna Ishchenko², Serge Steinfeld³, Adrien NZEUSSEU TOUKAP⁴, Dirk Elewaut⁵, Rik Lories⁶, Filip Van den bosch⁷ and Kurt de Vlam⁸, ¹Ghent University Hospital, Luxembourg, Luxembourg, ²University Hospitals Leuven, Sint-Stevens-Woluwe, Belgium, ³Clinique Saint-Jean, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁵Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁶KU Leuven, Leuven, Belgium, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁸University Hospitals Leuven, Leuven, Belgium
Background/Purpose: There is an ongoing debate on axial involvement in psoriatic arthritis (PsA). This study, using clinical and radiographical definitions of axial involvement, investigated the…
Abstract Number: 1015 • ACR Convergence 2022
Predictors of Nail Response with Guselkumab: A Post Hoc Analysis of the VOYAGE 2 Clinical Trial
Alexander Egeberg¹, William Tillett², Enikö Sonkoly³, Patricia Gorecki⁴, Anna Tjärnlund⁵, Jozefien Buyze⁶, Sven Wegner⁷ and Dennis McGonagle⁸, ¹Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Janssen-Cilag Ltd, High Wycombe, United Kingdom, ⁵Janssen-Cilag AB, Solna, Sweden, ⁶Janssen Pharmaceutica NV, Beerse, Belgium, ⁷Janssen-Cilag GmbH, Neuss, Germany, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Understanding factors that impact response to therapy may help improve disease management, clinical outcomes and patient quality of life. Nails are often overlooked in…
Abstract Number: 1012 • ACR Convergence 2022
Comparison of Sacroiliac CT Findings in Patients with and Without Psoriatic Arthritis: Results of the CASIPSA Study
Olivier Fakih¹, Andre Ramon², Clément Prati¹, Paul Ornetti³, Daniel Wendling⁴ and Frank Verhoeven¹, ¹Service de rhumatologie, CHU de Besançon, Besançon, France, ²University Hospital of DIJON, Rheumatology, Dijon, France, ³Service de rhumatologie, CHU de Dijon, Dijon, France, ⁴CHU, University Teaching Hospital, Besançon, France
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with various rheumatological manifestations, such as arthritis or enthesitis, predominantly in the peripheral skeleton. However, the…
Abstract Number: 1018 • ACR Convergence 2022
Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study
Dafna Gladman¹, Laura Coates², Laure Gossec³, Jacob Aelion⁴, Jitendra Vasandani⁵, Sue Cheng⁶, Lihua Tang⁶, Shauna Jardon⁷, Sven Richter⁶ and Philip J Mease⁸, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Sorbonne Université, Paris, France, ⁴West Tennessee Research Institute, Jackson, TN, ⁵West Texas Clinical Research, Lubbock, TX, ⁶Amgen, Inc., Thousand Oaks, CA, ⁷Amgen Inc., Gilbert, AZ, ⁸Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Oligoarticular psoriatic arthritis (PsA) is commonly reported in early disease. Although fewer joints are involved, there may be significant impact on patients’ (pts) quality…
Abstract Number: 1017 • ACR Convergence 2022
Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies
William Tillett¹, Laura Coates², Marijn Vis³, Joseph Merola⁴, Enrique R Soriano⁵, Michelle Perate⁶, May Shawi⁷, Miriam Zimmermann⁸, Emmanouil Rampakakis⁹, Mohamed Sharaf¹⁰, Peter Nash¹¹ and Philip Helliwell¹², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Erasmus MC Universitair Medisch Centrum, Rotterdam, Netherlands, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁹McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ¹⁰Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ¹¹School of Medicine, Griffith University, Sunshine Coast, Australia, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Though continuous composite measures of disease activity for psoriatic arthritis (PsA) assessment exist, abbreviated measures that are more feasible for screening in routine clinical…
Abstract Number: 1011 • ACR Convergence 2022
Trends in Fracture Rates Among Veterans with Ankylosing Spondylitis
Sali Merjanah¹, Jean Liew¹, John Bihn², Nathanael Fillmore², Nhan Do³ and Maureen Dubreuil⁴, ¹Boston University, Boston, MA, ²VA Boston Healthcare System, Boston, MA, ³VA Boston Healthcare System, Boston University School of Medicine, Boston, MA, ⁴Department of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: A meta-analysis demonstrated that the risk of vertebral fractures in Ankylosing Spondylitis (AS) is doubled compared to non-AS comparators. Increased fracture risk in AS…
Abstract Number: 0990 • ACR Convergence 2022
KPG-818, a Novel Cereblon (CRBN) Modulator, in Patients with SLE: Results of a Phase Ib Multiple Ascending Dose Study
RAMESH C. GUPTA¹, Paul Lunseth², Robert Levin³, Philip Waller⁴, Amber Khan⁵, Lester Hernandez⁵, Kai Wei⁶, Baisong Liao⁶, Tao Wang⁷, Kaiyue Hao⁷, Yanjiao Yin⁷ and Yong Guo⁷, ¹Shelby Research LLC, Memphis, TN, ²Clinical Research of West Florida, Tampa, FL, ³Clinical Research of West Florida. Inc., Clearwater, FL, ⁴Accurate Clinical Research, Houston, TX, ⁵Accurate Clinical Management, LLC., Houston, TX, ⁶Kangpu Biopharmaceuticals, Ltd., Shanghai, China, ⁷Kangpu Biopharmaceuticals, Ltd, Shanghai, China
Background/Purpose: KPG-818 is a novel CRL4-CRBN E3 ubiquitin ligase modulator that binds to CRBN with high affinity and leads to rapid and effective degradation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].